A Phase 3 interventional study of Masitinib and Placebo in Asthma, sponsored by AB Science. Completed at 8 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by AB Science · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.
Among the 296 studies in Asthma with a site in France, this one is the 65th largest by enrollment of the 204 interventional ones that give a count, is one of 12 that started in 2011, is one of 73 in phase 3, and was the 60th registered.
4,846 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, Argentina, Germany and 7 more countries
Ages 12–17
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 11 more countries
Ages 6+
Sanofi · Sites in France, United States, Canada and 3 more countries
Ages 6+
University Hospital, Montpellier · Sites in France
Ages 8–12
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
296 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 12 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 209 across the 204 interventional studies, 137 across the 92 observational. Of the 221 that completed or were terminated, 85 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 296 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06988358University Hospital, RouenEarly Identification of Children With Asthma | 2026-12-31 |
| NCT05734261University Hospital, MontpellierForced Oscillations Technique During a Metacholine Test in Children | 2027-02-06 |
| NCT04763447Assistance Publique - Hôpitaux de ParisShort Treatment with Omalizumab for Severe Asthma | 2027-05-20 |
Add all 10 to your calendar (.ics) → With an account.
Among the 296 studies in Asthma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. The objective of this study is to compare the efficacy and safety of masitinib at 6 mg/kg/day versus matched placebo in severe persistent asthma patients that is uncontrolled with oral corticosteroids. The primary outcome measure will be severe asthma exacerbation rate over duration of the treatment.
Main inclusion criteria:
Main exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
Drug: Masitinib
Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
Drug: Placebo
6 mg/kg/day
Also known as: AB1010
Also known as: Placebo Oral Tablet
Severe asthma exacerbation rate
The number of severe asthma exacerbations over time frame of outcome measure
Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
Asthma exacerbation rate
The number of asthma exacerbations over time frame of outcome measure
Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
ACQ Score
Asthma Control Questionnaire (ACQ) Score
Time frame: 36 weeks
Ran from Jan 2011 to primary completion in Nov 2019, 106 months.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 106 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib